Northbank Appointed by Cyclacel for European PR and IR

London, Manchester, Munich - 23 Nov 2007   Northbank Communications, the full service PR and marketing consultancy focused on science-based companies, has been chosen by Cyclacel for a PR and IR programme to raise the Company's profile and build relations with the European investment community.

Northbank has been appointed to raise the profile of Cyclacel with European investors through an integrated PR and IR programme. Sue Charles (CEO) will lead the account, supported by Justine Lamond, Account Manager and Claire Mosley, Junior Account Executive.

Cyclacel is a development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Listed on NASDAQ (NASDAQ:CYCC), Cyclacel is headquarted in New Jersey but retains its R&D base in Dundee, Scotland, the city of its foundation.

Commenting on the win, Sue Charles said:

"We are delighted to support Cyclacel with its PR and IR programme and we are looking forward to working with the management team to promote the Company to European investors."

© 2007 Northbank Communications